<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="other"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sensors (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Sensors (Basel)</journal-id><journal-id journal-id-type="publisher-id">sensors</journal-id><journal-title-group><journal-title>Sensors (Basel, Switzerland)</journal-title></journal-title-group><issn pub-type="epub">1424-8220</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11679946</article-id><article-id pub-id-type="doi">10.3390/s24248188</article-id><article-id pub-id-type="publisher-id">sensors-24-08188</article-id><article-categories><subj-group subj-group-type="heading"><subject>Perspective</subject></subj-group></article-categories><title-group><article-title>Safety of Immersive Virtual Reality for the Management of Parkinson&#x02019;s Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pimenta Silva</surname><given-names>Daniela</given-names></name><xref rid="af1-sensors-24-08188" ref-type="aff">1</xref><xref rid="af2-sensors-24-08188" ref-type="aff">2</xref><xref rid="af3-sensors-24-08188" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0263-8521</contrib-id><name><surname>Pona-Ferreira</surname><given-names>Filipa</given-names></name><xref rid="af3-sensors-24-08188" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Santos</surname><given-names>Beatriz</given-names></name><xref rid="af3-sensors-24-08188" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1706-5639</contrib-id><name><surname>Campo-Prieto</surname><given-names>Pablo</given-names></name><xref rid="af4-sensors-24-08188" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3756-2763</contrib-id><name><surname>Bou&#x000e7;a-Machado</surname><given-names>Raquel</given-names></name><xref rid="af2-sensors-24-08188" ref-type="aff">2</xref><xref rid="af3-sensors-24-08188" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Ferreira</surname><given-names>Joaquim J.</given-names></name><xref rid="af1-sensors-24-08188" ref-type="aff">1</xref><xref rid="af2-sensors-24-08188" ref-type="aff">2</xref><xref rid="af3-sensors-24-08188" ref-type="aff">3</xref><xref rid="c1-sensors-24-08188" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Medintz</surname><given-names>Igor</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Tamura</surname><given-names>Toshiyo</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-sensors-24-08188"><label>1</label>Centro de Estudos Egas Moniz, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal; <email>dsilva7@edu.ulisboa.pt</email></aff><aff id="af2-sensors-24-08188"><label>2</label>Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal</aff><aff id="af3-sensors-24-08188"><label>3</label>CNS&#x02014;Campus Neurol&#x000f3;gico, 2560-280 Torres Vedras, Portugal</aff><aff id="af4-sensors-24-08188"><label>4</label>HealthyFit Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, 36313 Vigo, Spain; <email>pcampo@uvigo.gal</email></aff><author-notes><corresp id="c1-sensors-24-08188"><label>*</label>Correspondence: <email>jferreira@medicina.ulisboa.pt</email></corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>24</volume><issue>24</issue><elocation-id>8188</elocation-id><history><date date-type="received"><day>18</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>19</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>20</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Virtual reality (VR) has been used in research and clinical practice in the management of Parkinson&#x02019;s disease (PD), potentially enhancing physiotherapy. Adverse events (AEs) associated with VR applications in PD have been poorly explored. We conducted a randomized controlled trial to compare two 12-week interventions using physiotherapy and immersive VR, and analyzed the frequency and type of AEs occurring in 30 people with PD. We reported 144 AEs (8.4% of the sessions), predominantly classified as mild and unrelated to the interventions. Two were serious AEs, one leading to study discontinuation. Notably, discomfort/pain, motor fluctuations, and falls were the most frequently reported, accounting for 63% of the total AEs. Five falls were definitely associated with the &#x02018;sense of presence&#x02019; provided by the fully immersive VR system, which underscores the necessity for careful game selection when designing interventions for PD. Motor fluctuations may have been associated with various factors, which merit further investigation. We also explored the role of SSQ as a measure of cybersickness in PD. In conclusion, it is important to closely monitor and characterize AEs to ensure safety and efficacy in clinical practice as AEs may be more common than previously recognized in VR interventions in PD.</p></abstract><kwd-group><kwd>neurorehabilitation</kwd><kwd>physiotherapy</kwd><kwd>exercise</kwd><kwd>virtual reality</kwd><kwd>virtual reality exposure therapy</kwd><kwd>Parkinson&#x02019;s disease</kwd><kwd>safety</kwd><kwd>adverse events</kwd></kwd-group><funding-group><award-group><funding-source>Pr&#x000e9;mio Jo&#x000e3;o Lobo Antunes 2021&#x02014;Santa Casa da Miseric&#x000f3;rdia de Lisboa</funding-source></award-group><funding-statement>This research was funded by Pr&#x000e9;mio Jo&#x000e3;o Lobo Antunes 2021&#x02014;Santa Casa da Miseric&#x000f3;rdia de Lisboa.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-sensors-24-08188"><title>1. Introduction</title><p>Nonpharmacological interventions are one of the pillars of the complex management of neurodegenerative disorders. In Parkinson&#x02019;s disease (PD), these interventions complement pharmacological and neurosurgical strategies and play a key role in targeting disease-specific impairments, tailored to each individuals&#x02019; needs, from mild to more advanced disease stages. These may include different combinations of physiotherapy and clinical exercise, occupational, speech, and psychology therapies, nutritional advice, social support, among others. Physiotherapy and clinical exercise are thus part of a holistic multidisciplinary care [<xref rid="B1-sensors-24-08188" ref-type="bibr">1</xref>], guided by the European Physiotherapy Guideline for PD [<xref rid="B2-sensors-24-08188" ref-type="bibr">2</xref>] and the principles of exercise by the American College of Sports Medicine (ACSM). Current recommendations are to combine various exercise modalities to engage people with PD in enjoyable and feasible regimens, while focusing on person-specific needs and individual preferences [<xref rid="B2-sensors-24-08188" ref-type="bibr">2</xref>]. A recent Cochrane review confirmed that most types of physical exercise are beneficial in improving motor signs and quality of life of individuals with PD [<xref rid="B3-sensors-24-08188" ref-type="bibr">3</xref>].</p><p>Notwithstanding the proven efficacy of physiotherapy, safety is one important but often neglected subject [<xref rid="B3-sensors-24-08188" ref-type="bibr">3</xref>,<xref rid="B4-sensors-24-08188" ref-type="bibr">4</xref>]. The 2023 Cochrane review demonstrated that only 85 out of the 156 included randomized controlled trials (RCT) that provided some kind of safety data, while only 28 studies reported the occurrence of adverse events (AEs) [<xref rid="B3-sensors-24-08188" ref-type="bibr">3</xref>]. As people with PD tend to underreport adverse drug reactions spontaneously [<xref rid="B5-sensors-24-08188" ref-type="bibr">5</xref>], it is difficult to determine whether the low frequency of AEs in studies on nonpharmacological interventions follows an actual absence of an AE or an inadequate assessment. Using a structured and systematic approach to record AEs during and after specialized physiotherapy sessions for Parkinsonian patients, our study group previously reported a total of 128 AEs, which occurred in 7% of the sessions [<xref rid="B6-sensors-24-08188" ref-type="bibr">6</xref>]. Although physiotherapy should still be considered safe, this study underlines the need to actively inquire patients about adverse reactions to exercise since they may be more frequent than usually reported [<xref rid="B6-sensors-24-08188" ref-type="bibr">6</xref>].</p><p>Virtual reality (VR) and exergaming are being increasingly used in research studies and clinical practice as tools to complement traditional physiotherapy and exercise. By providing multisensory stimuli and demanding constant interactivity, both VR and exergaming enhance feedback about performance and results, challenge motor and cognitive processes simultaneously, and motivate individuals to actively engage in exercise. Several studies have demonstrated the efficacy of VR in several clinical outcomes [<xref rid="B7-sensors-24-08188" ref-type="bibr">7</xref>,<xref rid="B8-sensors-24-08188" ref-type="bibr">8</xref>,<xref rid="B9-sensors-24-08188" ref-type="bibr">9</xref>,<xref rid="B10-sensors-24-08188" ref-type="bibr">10</xref>,<xref rid="B11-sensors-24-08188" ref-type="bibr">11</xref>,<xref rid="B12-sensors-24-08188" ref-type="bibr">12</xref>]. Nevertheless, as in interventions with traditional physiotherapy, AEs have been poorly reported. Cybersickness is a common concern, especially in studies using head-mounted displays (HMDs) [<xref rid="B13-sensors-24-08188" ref-type="bibr">13</xref>], which are technologies promoting immersive experiences by cancelling the real-world surroundings thus increasing the sense of presence within the virtual environment [<xref rid="B14-sensors-24-08188" ref-type="bibr">14</xref>]. Yet, it appears to be an uncommon adverse reaction, even when assessed through questionnaires [<xref rid="B15-sensors-24-08188" ref-type="bibr">15</xref>,<xref rid="B16-sensors-24-08188" ref-type="bibr">16</xref>], while other AEs associated with exercise might be overlooked (e.g., falls, pain) [<xref rid="B6-sensors-24-08188" ref-type="bibr">6</xref>].</p><p>In this paper, we aim to explore the occurrence of AEs during interventions combining immersive VR (IVR) systems with physiotherapy in the management of PD. We will further characterize the type of AEs and their relationship with the interventions. We hope to guide future experimental studies using VR to improve AEs recognition and ensure safety and efficacy.</p></sec><sec sec-type="methods" id="sec2-sensors-24-08188"><title>2. Methods</title><p>We conducted an open label rater-blinded, randomized controlled trial at CNS-Campus Neurol&#x000f3;gico, a specialized movement disorder center in Portugal, to evaluate the efficacy, safety, and usability of using IVR through an HMD device as a complement to a specialized physiotherapy program into the management of functional mobility with cognitive dual-tasking in PD. The study protocol is further described in ClinicalTrials.gov under the identifier NCT06052930. For the purpose of this paper, we will focus on AE-related data to characterize the frequency, type, and severity of AEs and their causal relationship with interventions that combine physiotherapy and IVR. We will also explore cybersickness-related symptoms.</p><p>Individuals with mild to moderate PD (Hoehn and Yahr (HY) stage 1 to 3), and able to perform Timed Up and Go (TUG) test unassisted in less than 11.5 s [<xref rid="B17-sensors-24-08188" ref-type="bibr">17</xref>,<xref rid="B18-sensors-24-08188" ref-type="bibr">18</xref>] on medication were randomly assigned to either perform a 12-week combination program with PD-specialized physiotherapy plus IVR (VR group, VRG), or a sequential program starting with 6 weeks of PD-specialized physiotherapy alone followed by 6 weeks of the combination of physiotherapy and VR (sequential group, SG).</p><p>Each IVR training session started with 6 to 8 min of warm-up, followed by 20 min of boxing, using a commercially available HMD, the HTC Vive&#x02122; Pro (HTC Corp., Taoyuan City, Taiwan). The NVIDIA<sup>&#x000ae;</sup> VR Fun House experience is available on the Steam VR store (<uri xlink:href="https://store.steampowered.com/">https://store.steampowered.com/</uri>, accessed on 15 October 2024). It was used as a warm-up, where participants were required to perform different tasks at a funfair, such as throwing objects, archery, or handling a sword. The following boxing experience was a high-intensity training performed using the exergame BOX VR (available on the Steam Store <uri xlink:href="https://store.steampowered.com/">https://store.steampowered.com/</uri>, accessed on 15 October 2024). It involved performing boxing movements in response to the randomly presented stimuli, which required coordinated movements of the upper limbs, trunk, head, and lower limbs. It incorporated variations in stance, squats, and lateral movements within a gym scenario boosted by motivating music. Regarding the PD-specialized physiotherapy sessions, it was delivered in accordance with recommendations from the European Physiotherapy Guideline for PD [<xref rid="B2-sensors-24-08188" ref-type="bibr">2</xref>], lasting 60 min each session. IVR and physiotherapy were delivered on the same day, three times per week. Participants were supervised by the study investigators who were physiotherapists experienced in PD rehabilitation (FPF and BS), and a neurologist experienced in IVR training in individuals with PD (DPS).</p><p>All AEs were systematically recorded by the investigators using a similar approach to a previously applied approach for a physiotherapy intervention in Parkinsonian patients [<xref rid="B6-sensors-24-08188" ref-type="bibr">6</xref>]. Investigators were asked to remain vigilant and to document any type of event. A list of AEs was provided in advance to enhance their identification and ensure consistency in description, regardless of whether the AE was observed during sessions or reported spontaneously by participants. Therefore, we used an adapted form where investigators would describe the event, detailing the type of AE, timing (whether it occurred during or after the session), the intervention associated with it, severity, and investigators&#x02019; assessment of its causality. For the purpose of this study, AEs were defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the physiotherapy and/or IVR sessions that may or may not be considered related to the intervention [<xref rid="B6-sensors-24-08188" ref-type="bibr">6</xref>,<xref rid="B19-sensors-24-08188" ref-type="bibr">19</xref>]. Severity was graded according to the investigators&#x02019; best clinical judgment using the Common Terminology Criteria for Adverse Events (CTCAE) as mild, moderate, severe, life-threatening, or death-related [<xref rid="B6-sensors-24-08188" ref-type="bibr">6</xref>,<xref rid="B20-sensors-24-08188" ref-type="bibr">20</xref>]. A serious AE was considered when the participant outcome was death, life-threatening, hospitalization, disability, or permanent damage, or an intervention was required to prevent harm [<xref rid="B21-sensors-24-08188" ref-type="bibr">21</xref>]. Regarding causality, investigators categorized each AE as definitely, possibly, improbably, or unrelated to the interventions, using the World Health Organization Upsala Monitoring Centre (WHO-UMC) causality assessment system [<xref rid="B6-sensors-24-08188" ref-type="bibr">6</xref>,<xref rid="B22-sensors-24-08188" ref-type="bibr">22</xref>].</p><p>In addition to this detailed approach of AE reporting, we used the Simulator Sickness Questionnaire (SSQ) [<xref rid="B23-sensors-24-08188" ref-type="bibr">23</xref>,<xref rid="B24-sensors-24-08188" ref-type="bibr">24</xref>] to actively enquire participants about cybersickness-related symptoms at baseline, at the end of each session during the first two weeks, and at the end of the 6th and 12th weeks, thus enabling us to evaluate the evolution of SSQ scores over time, as previously suggested [<xref rid="B25-sensors-24-08188" ref-type="bibr">25</xref>]. The SSQ was originally designed to measure simulator sickness associated with military flight simulators, and consists of 16 items assessed on a four-point scale, according to the degree of presence of the symptom (0&#x02014;absent; 4&#x02014;severe). This tool has been widely used to measure the perception of cybersickness symptoms related to VR systems in the general population [<xref rid="B23-sensors-24-08188" ref-type="bibr">23</xref>].</p><p>We characterized the sample at baseline and the AEs using a descriptive analysis.</p></sec><sec sec-type="results" id="sec3-sensors-24-08188"><title>3. Results</title><p>Thirty participants were randomly assigned to one of the training groups. The VRG had a median [interquartile range, IQR] age of 61 [58, 66] years, a median disease duration of 7 [6, 19] years, a median MDS-UPDRS part 3 score of 31 [23, 35.5], and a median Hoehn and Yahr (HY) of 2 [2, 2]. The SG had a median age of 68 [62, 72.5] years, a median disease duration of 9 [5, 11.5] years, a median MDS-UPDRS part 3 score of 23 [13, 24.5], and a median HY of 2 [2, 2]. Baseline characteristics are summarized in <xref rid="sensors-24-08188-t001" ref-type="table">Table 1</xref>.</p><p>The total number of sessions held was 1717. The VRG attended 1012 sessions, including both VR and physiotherapy sessions during the whole study duration, whereas the SG attended 705 sessions, comprising physiotherapy alone during the first 6 weeks and physiotherapy plus IVR during the following 6 weeks of this study.</p><p><xref rid="sensors-24-08188-t002" ref-type="table">Table 2</xref> presents the AEs that occurred in each group throughout this study. In total, 144 AEs were reported over the 12-week intervention, which corresponds to 8.4% of the attended sessions. Eighty-six AEs occurred in the VRG, accounting for 8.5% of the attended sessions, while 58 were recorded in the SG, accounting for 8.2% of the attended sessions. A total of 23 (76.7%) participants experienced more than one AE, with 12 from the VR group and 11 from the sequential group. For one patient in the sequential group, the AE was reason to discontinue the intervention shortly after it started.</p><sec id="sec3dot1-sensors-24-08188"><title>3.1. Frequency and Type of Adverse Event, Setting, and Causality</title><p>The most frequent AEs were discomfort/pain, motor fluctuations, and falls, which occurred in 2.7%, 2%, and 0.6% of total attended sessions, respectively. These three events represented 63.2% of all AEs. Overall, 77 (53.5%) AEs were recorded during or after IVR sessions, while physiotherapy sessions were associated with 30 (20.8%) events.</p><p>Most AEs (52.1%) were classified as unrelated or improbably related to study interventions. For the IVR training, 28 AEs were considered possibly related, and 16 definitely related, while for the physiotherapy sessions, 14 were deemed possibly related, and 2 definitely related. The AEs possibly to definitely related to IVR training included motor fluctuations (<italic toggle="yes">n</italic> = 17), discomfort/pain (<italic toggle="yes">n</italic> = 16), falls (<italic toggle="yes">n</italic> = 5), fatigue/tiredness (<italic toggle="yes">n</italic> = 3), irritability/frustration (<italic toggle="yes">n</italic> = 2), and dizziness (<italic toggle="yes">n</italic> = 1). The AEs potentially related to physiotherapy sessions consisted of discomfort/pain (<italic toggle="yes">n</italic> = 6), hypotension (<italic toggle="yes">n</italic> = 3), hyperhidrosis (<italic toggle="yes">n</italic> = 3), cramps (<italic toggle="yes">n</italic> = 1), dizziness (<italic toggle="yes">n</italic> = 1), fatigue/tiredness (<italic toggle="yes">n</italic> = 1), and hematuria (<italic toggle="yes">n</italic> = 1). Fifteen (10.4%) AEs were experienced during or after both the IVR and physiotherapy sessions.</p><p>In the following sections, we will further characterize the three most common AEs.</p><sec id="sec3dot1dot1-sensors-24-08188"><title>3.1.1. Discomfort/Pain</title><p>Experienced by 15 participants, discomfort/pain occurred during or after sessions in 30 out of the 46 events, more frequently during IVR training (<italic toggle="yes">n</italic> = 22). The nature of the discomfort/pain was presumably musculoskeletal in most cases, namely lumbar pain and arthralgia. However, in some cases (<italic toggle="yes">n</italic> = 12), the pain was located on the side most affected by PD.</p></sec><sec id="sec3dot1dot2-sensors-24-08188"><title>3.1.2. Motor Fluctuations</title><p>A diary of motor complications had not been planned; therefore, the reported motor fluctuations were those observed by the investigators during sessions.</p><p>The 34 events were noticed in five participants, occurring more frequently during IVR training sessions (<italic toggle="yes">n</italic> = 28), typically after 10 to 18 min of intense exercise with the IVR boxing game. In some cases, motor fluctuations had an impact on exercise performance, with sessions having to be interrupted to rest, or decrease the difficulty of the game.</p><p>Twenty-six of the total events were due to two participants only. In both cases, participants already presented motor fluctuations at baseline, as measured by item 3 of the MDS-UPDRS part 4. Yet, they judged these events potentially triggered by the physical exertion and fatigue, as they occurred suddenly and unexpectedly in the middle of the sessions. Therefore, the exercise may have triggered a &#x0201d;wearing-off&#x0201d; phenomenon or exacerbated an OFF episode, since the motor fluctuations appeared approximately 3.5 h after the previous dose intake. These were similar to those occurring at home, comprising a reemergence of Parkinsonian tremor, bradykinesia, rigidity, painful OFF dystonia, gait disturbance, and freezing of gait, as described by participants.</p></sec><sec id="sec3dot1dot3-sensors-24-08188"><title>3.1.3. Falls</title><p>Eleven falls were reported during this study, either self-reported by participants or observed during sessions. Five of these uninjured falls occurred in exactly the same circumstance during the IVR training sessions, which were deemed definitely related to the intervention, as a consequence of the &#x02018;sense of presence&#x02019; provided by the HMD. In the funfair scenario, participants were required to grab balls and other objects from a virtual table, and throw them to break dishes displayed on a shelf. As represented in <xref rid="sensors-24-08188-f001" ref-type="fig">Figure 1</xref>, the balls had different sizes and were distributed on the table, with some being more reachable than others. These five falls were caused by participants leaning over the virtual table with the support of one hand to grab a ball further away, thus reaching a point of imbalance in the real world. These participants were HY of 2, and did not have significant postural instability. All the other falls occurred after or between sessions and were considered not related to the study trainings.</p></sec></sec><sec id="sec3dot2-sensors-24-08188"><title>3.2. Severity of Adverse Events</title><p>AEs were mostly mild (<italic toggle="yes">n</italic> = 99, 68.8%), representing mild symptoms or asymptomatic. Forty-one (28.5%) were graded as moderate, with minimal, local, or noninvasive intervention indicated, while two (1.4%) were considered severe or medically significant, limiting self-care activities of daily living. Two AEs (1.4%) were classified as serious, requiring inpatient hospitalization and urgent surgical treatment. One involved a fall at home resulting in a hip fracture, and the other an incarcerated hernia. Both severe and serious AEs were deemed unrelated to the interventions.</p></sec><sec id="sec3dot3-sensors-24-08188"><title>3.3. Cybersickness</title><p>The baseline mean SSQ score was 54.2 (&#x000b1;95.56), already indicating concerning levels of cybersickness symptoms [<xref rid="B23-sensors-24-08188" ref-type="bibr">23</xref>] even before using the IVR system, which may simply represent the overlap between the SSQ 16 items and PD symptoms. Nevertheless, as represented in <xref rid="sensors-24-08188-f002" ref-type="fig">Figure 2</xref>, the mean SSQ scores remained stable throughout this study relative to baseline, varying from 52.2 (&#x000b1;31.86) and 73.3 (&#x000b1;42.05). The SSQ items more frequently scored above 0 were fatigue and sweating, with some participants mentioning increased salivation, blurred vision, eyestrain, difficulty focusing and concentrating, fullness of head, and headache, some of which were already present at baseline.</p></sec></sec><sec sec-type="discussion" id="sec4-sensors-24-08188"><title>4. Discussion</title><p>In this paper, we comprehensively described the AEs reported during an RCT investigating the combination of physiotherapy and IVR in the management of PD. Using a structured approach, we found that 144 AEs were recorded over 12 weeks, corresponding to 8.4% of the sessions held. This rate is lower than typically reported for pharmacological interventions, comparable to the AE frequency observed in physiotherapy sessions for Parkinsonian patients [<xref rid="B6-sensors-24-08188" ref-type="bibr">6</xref>], and higher than usually reported for VR interventions [<xref rid="B16-sensors-24-08188" ref-type="bibr">16</xref>,<xref rid="B26-sensors-24-08188" ref-type="bibr">26</xref>].</p><p>To the best of our knowledge, this is the first time that such a detailed description has been made to characterize AEs during interventions using VR in PD. While we recognize that the AE profile may change between different types of VR, many studies lack information regarding the occurrence of AEs [<xref rid="B12-sensors-24-08188" ref-type="bibr">12</xref>,<xref rid="B26-sensors-24-08188" ref-type="bibr">26</xref>,<xref rid="B27-sensors-24-08188" ref-type="bibr">27</xref>,<xref rid="B28-sensors-24-08188" ref-type="bibr">28</xref>,<xref rid="B29-sensors-24-08188" ref-type="bibr">29</xref>,<xref rid="B30-sensors-24-08188" ref-type="bibr">30</xref>,<xref rid="B31-sensors-24-08188" ref-type="bibr">31</xref>,<xref rid="B32-sensors-24-08188" ref-type="bibr">32</xref>,<xref rid="B33-sensors-24-08188" ref-type="bibr">33</xref>,<xref rid="B34-sensors-24-08188" ref-type="bibr">34</xref>]. Other studies report no AE [<xref rid="B15-sensors-24-08188" ref-type="bibr">15</xref>,<xref rid="B35-sensors-24-08188" ref-type="bibr">35</xref>,<xref rid="B36-sensors-24-08188" ref-type="bibr">36</xref>,<xref rid="B37-sensors-24-08188" ref-type="bibr">37</xref>,<xref rid="B38-sensors-24-08188" ref-type="bibr">38</xref>,<xref rid="B39-sensors-24-08188" ref-type="bibr">39</xref>,<xref rid="B40-sensors-24-08188" ref-type="bibr">40</xref>] which, despite reassuring, raises questions about whether AEs have been adequately monitored or reported in these clinical trials. Studies reporting AEs infrequently attribute them to any of the interventions, or there are insufficient details about causality. Two well-conducted RCTs, the V-TIME study [<xref rid="B7-sensors-24-08188" ref-type="bibr">7</xref>] and the Park-in-Shape trial [<xref rid="B8-sensors-24-08188" ref-type="bibr">8</xref>], have reported AEs in aerobic training using VR. The V-TIME study, comparing treadmill training alone with treadmill training augmented by VR in elderly people with a risk of falls, reported 28 AEs over 6 weeks, all leading to study discontinuation, five of which were serious AEs [<xref rid="B7-sensors-24-08188" ref-type="bibr">7</xref>]. Although the approach is not fully described, the authors state that the causality was investigated and none were related to the interventions [<xref rid="B7-sensors-24-08188" ref-type="bibr">7</xref>]. Regarding the Park-in-Shape trial, 27 AEs were reported in individuals with PD performing a home-based training on a stationary bicycle enhanced by VR during 6 months; three were serious AEs [<xref rid="B8-sensors-24-08188" ref-type="bibr">8</xref>]. The authors reported that seven AEs were potentially exercise-related, including arthralgia, back pain, and palpitations [<xref rid="B8-sensors-24-08188" ref-type="bibr">8</xref>]. Nevertheless, there is no detailed description of how AEs were documented and characterized.</p><p>In our study, three AEs accounted for more than half (63%) of the total events, including discomfort/pain, motor fluctuations and falls. Pain and falls were already described as being among the most frequent AEs in physiotherapy interventions and exercise-related injuries [<xref rid="B6-sensors-24-08188" ref-type="bibr">6</xref>,<xref rid="B41-sensors-24-08188" ref-type="bibr">41</xref>,<xref rid="B42-sensors-24-08188" ref-type="bibr">42</xref>,<xref rid="B43-sensors-24-08188" ref-type="bibr">43</xref>]. Regarding pain, it has been considered related to endurance exercises in 8.5% to 23.9% of the patients, especially when exercises are strenuous [<xref rid="B8-sensors-24-08188" ref-type="bibr">8</xref>,<xref rid="B41-sensors-24-08188" ref-type="bibr">41</xref>]. We found that discomfort/pain were probably/definitely related to the interventions in 43% of the participants, mostly to IVR training, which was also aerobic and intense. Although being the most frequent AE, it occurred in less than 3% of the attended sessions and was mostly mild in severity. Similar to other studies, pain was presumably musculoskeletal in most cases, including back pain and arthralgias. However, in 12 cases, the pain occurred in the most affected side of the disease. While we could not establish the exact cause or associate it with OFF periods, we speculate that it may be an exacerbation of a previous pain, caused by the fast and big amplitudes that the VR boxing training demanded, which challenged the spontaneously slower and smaller movements of the more rigid and bradykinetic limb. In addition, hand dominance and the disease asymmetry may have added to this limiting factor. To our knowledge, this phenomenon has not been previously described in VR users with PD, and further studies should investigate its nature and impact, to enable the development of an individualized approach for susceptible individuals.</p><p>Falls in physiotherapy and exercise interventions, with or without VR, have been rare and non-injurious, albeit circumstances being often poorly described [<xref rid="B7-sensors-24-08188" ref-type="bibr">7</xref>,<xref rid="B8-sensors-24-08188" ref-type="bibr">8</xref>,<xref rid="B41-sensors-24-08188" ref-type="bibr">41</xref>,<xref rid="B42-sensors-24-08188" ref-type="bibr">42</xref>,<xref rid="B43-sensors-24-08188" ref-type="bibr">43</xref>]. Previous studies using fully immersive VR systems in older adults and in people with PD have no reported falls, thus considering them safe for boxing training [<xref rid="B40-sensors-24-08188" ref-type="bibr">40</xref>] and walking [<xref rid="B15-sensors-24-08188" ref-type="bibr">15</xref>], including in an antigravity treadmill setting [<xref rid="B16-sensors-24-08188" ref-type="bibr">16</xref>], although patients were secured with safety harnesses to prevent falls. In our study, we encountered 11 falls, 6 of them unrelated to the intervention, with one resulting in a hip fracture. Interestingly, we observed five falls occurring under identical conditions, which could not be better explained by underlying postural instability. Instead, these falls were definitely caused by the &#x02018;sense of presence&#x02019; that the fully immersive virtual environment induced [<xref rid="B44-sensors-24-08188" ref-type="bibr">44</xref>]. In our view, the discrepancy between the virtual environment and the real-word actions, along with the HMD&#x02019;s ability to cancel the real surroundings, makes IVR systems susceptible to these types of events. Therefore, we suggest to avoid games that place users in imbalanced positions or involve actions incongruent with the physical environment, and to carefully provide safety measures to prevent serious complications. In addition, it is advisable to supervise fully immersive VR interventions at all times, or provide exergames with sitting positions to prevent falls in home-based use [<xref rid="B39-sensors-24-08188" ref-type="bibr">39</xref>]. People with an increased risk of falls and postural instability may present additional limitations to the implementation of IVR, thus its safety in this group of individuals needs careful investigation.</p><p>Motor fluctuations have not been described in other studies with VR, while we observed them in 2% of the attended sessions. Three main reasons may have contributed to the increased rate of this AE in our study. First, considering that participants already experienced motor fluctuations at baseline and that they were observed approximately 3.5 h from the last levodopa intake, these episodes likely reflected an exacerbation of their usual &#x0201c;wearing-off&#x0201d; phenomenon caused by exercise. Second, the same patient may have presented the same AE several times due to the episodic nature of motor fluctuations and their possible relation to the moment of exercise. Third, the investigators&#x02019; had an increased awareness to report all events during the study period. Although sessions were scheduled to be optimized by participants&#x02019; ON state based on their preferred timing and perceived ideal exercise window, these events often emerged suddenly after some time of intense aerobic exercise. We hypothesize that physical exertion may have either worsened motor fluctuations or triggered OFF episodes. However, it is controversial whether physical exercise has a triggering or an attenuating effect on OFF symptoms [<xref rid="B45-sensors-24-08188" ref-type="bibr">45</xref>,<xref rid="B46-sensors-24-08188" ref-type="bibr">46</xref>]. For some patients, exercise is a coping strategy to overcome an OFF episode [<xref rid="B45-sensors-24-08188" ref-type="bibr">45</xref>], whereas for others it can be a source of increased fatigue [<xref rid="B47-sensors-24-08188" ref-type="bibr">47</xref>], which is a trigger of OFF episodes [<xref rid="B45-sensors-24-08188" ref-type="bibr">45</xref>]. A recent study found that people with advanced PD (PD with motor complications, mean disease duration of 8.7 &#x000b1; 5.9 years) were more likely to worsen motor scores immediately after physical exercise than patients with milder disease, which did not seem to be caused by changes in the levodopa pharmacokinetics after exercise [<xref rid="B46-sensors-24-08188" ref-type="bibr">46</xref>]. While it may be an explanation for this &#x02018;acute&#x02019; phenomenon in our study, we can not exclude that other factors unrelated to exercise may have played a role, such as stress, anxiety, or lack of sleep [<xref rid="B45-sensors-24-08188" ref-type="bibr">45</xref>]. In addition, it is not known whether the type of VR system may have a triggering effect on motor fluctuations, particularly regarding the intensity, velocity, and variety of visual stimuli, the complexity of the VR environment, and the level of immersion.</p><p>Cybersickness is a frequent safety concern in studies using IVR, though in practice it is rarely reported. While SSQ was originally designed for military flight simulators, it has been used to measure motion sickness related to the use of VR systems [<xref rid="B25-sensors-24-08188" ref-type="bibr">25</xref>]. These symptoms are then clustered into categories representing symptoms of nausea, oculomotor disturbance, and disorientation, and summed up into a total simulator sickness score [<xref rid="B23-sensors-24-08188" ref-type="bibr">23</xref>]. Based on the original military sample, total scores can be associated with negligible (under 5), minimal (between 5 and 10), significant (between 10 and 15), and concerning (between 15 and 20) symptoms [<xref rid="B23-sensors-24-08188" ref-type="bibr">23</xref>]. Although the scale seems appropriate for VR research, measuring cybersickness only after exposure presumes that participants are perfectly well before the exposure [<xref rid="B25-sensors-24-08188" ref-type="bibr">25</xref>]. In fact, comparing the SSQ 16 items and PD symptoms, the overlap is unquestionable (e.g., general discomfort, fatigue, difficulty focusing, increased salivation, sweating, nausea, difficulty concentrating, and dizziness), thus explaining why mean scores already indicated concerning levels of cybersickness before VR exposure in our participants. Therefore, while SSQ might not be totally appropriate in individuals with PD, we measured SSQ at baseline and at different timepoints, following prior recommendations [<xref rid="B25-sensors-24-08188" ref-type="bibr">25</xref>], and we found that mean scores remained stable across all assessments, including when compared to baseline. The most common scored symptoms after VR exposure were fatigue and sweating, which are most likely related to the boxing aerobic exercise. Our findings are consistent with previous studies suggesting that motion sickness may not be a significant concern in most cases [<xref rid="B40-sensors-24-08188" ref-type="bibr">40</xref>,<xref rid="B48-sensors-24-08188" ref-type="bibr">48</xref>]. Nonetheless, factors such as game content, type of visual stimulation, time of exposure, and age, which have been linked to VR-related sickness [<xref rid="B13-sensors-24-08188" ref-type="bibr">13</xref>], should be taken into consideration when applying IVR to PD patients.</p><p>Our study has some limitations. First, we included participants with mild to moderate PD, with and without motor complications, which may have different AE profiles. Second, session schedules were chosen according to participants&#x02019; preferences and their reported optimal ON window, which in some cases may not necessarily mean the best time to perform intense physical activity, especially in individuals with known motor fluctuations not used to exercising. This may have influenced the increased reporting of OFF episodes and other AEs during sessions. Scheduling exercise between one to two hours from the last levodopa intake may better overcome this limitation. Third, we did not perform a comparative analysis between study groups nor between VR and physiotherapy interventions, therefore, we cannot conclude on the causality of the increased rate of AEs. Despite these limitations, we believe our study provides critical insights for informing future research in AE reporting in interventions for PD.</p><p>Taken together, we consider that physiotherapy combined with IVR can be considered safe for the management of PD, with AEs occurring in fewer than 10% of sessions, being mostly mild and not related to the interventions themselves. The frequency and type of AEs were similar to those previously described for traditional physiotherapy; however, we highlight the overall higher rate when compared to what was previously reported for VR interventions, as well as the frequent occurrence of motor fluctuations. This difference likely reflects the investigators&#x02019; increased awareness for reporting, alongside our structured approach to identifying and characterizing these events. Further investigation is needed to ascertain whether the type of VR, the level of immersion (immersive vs. non-immersive), visual stimulus intensity, session duration, the exercise intensity, disease duration, and timing of the last levodopa intake may influence the AEs profile during VR interventions in PD. Falls are a significant concern when using IVR systems, especially in people with PD, and should be anticipated when selecting games or devices.</p></sec><sec sec-type="conclusions" id="sec5-sensors-24-08188"><title>5. Conclusions</title><p>We suggest that AEs may be more common in sessions combining VR and physiotherapy than previously recognized, although we still consider it a safe intervention. It is therefore important to plan ahead with risk minimization strategies and ensure safety and efficacy when using VR for the management of PD. Future studies should replicate our approach in AE reporting to better characterize the relationship between the events and type of VR intervention.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, D.P.S., R.B.-M., P.C.-P. and J.J.F.; methodology, D.P.S., F.P.-F., B.S., R.B.-M., P.C.-P. and J.J.F.; writing&#x02014;original draft preparation, D.P.S.; writing&#x02014;review and editing, F.P.-F., B.S., R.B.-M., P.C.-P. and J.J.F.; supervision, J.J.F.; funding acquisition, D.P.S. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>This study was conducted in accordance with the Declaration of Helsinki, and approved by the CNS Ethics Committee (Ref. 11-2022).</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in this study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in this study are included in the article. Further inquiries can be directed to the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest. The funders had no role in the design of this study, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.</p></notes><ref-list><title>References</title><ref id="B1-sensors-24-08188"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bloem</surname><given-names>B.R.</given-names></name>
<name><surname>Okun</surname><given-names>M.S.</given-names></name>
<name><surname>Klein</surname><given-names>C.</given-names></name>
</person-group><article-title>Parkinson&#x02019;s disease</article-title><source>Lancet</source><year>2021</year><volume>397</volume><fpage>2284</fpage><lpage>2303</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00218-X</pub-id><pub-id pub-id-type="pmid">33848468</pub-id>
</element-citation></ref><ref id="B2-sensors-24-08188"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Keus</surname><given-names>S.</given-names></name>
<name><surname>Munneke</surname><given-names>M.</given-names></name>
<name><surname>Graziano</surname><given-names>M.</given-names></name>
<name><surname>Paltamaa</surname><given-names>J.</given-names></name>
<name><surname>Pelosin</surname><given-names>E.</given-names></name>
<name><surname>Domingos</surname><given-names>J.</given-names></name>
<name><surname>Br&#x000fc;hlmann</surname><given-names>S.</given-names></name>
<name><surname>Ramaswamy</surname><given-names>B.</given-names></name>
<name><surname>Prins</surname><given-names>J.</given-names></name>
<name><surname>Struiksma</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>European Physiotherapy Guideline for Parkinson&#x02019;s disease</article-title><source>KNGF/Park. Neth.</source><year>2014</year><volume>191</volume><fpage>1</fpage><lpage>153</lpage></element-citation></ref><ref id="B3-sensors-24-08188"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ernst</surname><given-names>M.</given-names></name>
<name><surname>Folkerts</surname><given-names>A.K.</given-names></name>
<name><surname>Gollan</surname><given-names>R.</given-names></name>
<name><surname>Lieker</surname><given-names>E.</given-names></name>
<name><surname>Caro-Valenzuela</surname><given-names>J.</given-names></name>
<name><surname>Adams</surname><given-names>A.</given-names></name>
<name><surname>Cryns</surname><given-names>N.</given-names></name>
<name><surname>Monsef</surname><given-names>I.</given-names></name>
<name><surname>Dresen</surname><given-names>A.</given-names></name>
<name><surname>Roheger</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Physical exercise for people with Parkinson&#x02019;s disease: A systematic review and network meta-analysis</article-title><source>Cochrane Database Syst. Rev.</source><year>2023</year><volume>1</volume><fpage>CD013856</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD013856.pub2</pub-id><pub-id pub-id-type="pmid">36602886</pub-id>
</element-citation></ref><ref id="B4-sensors-24-08188"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Allen</surname><given-names>N.E.</given-names></name>
<name><surname>Sherrington</surname><given-names>C.</given-names></name>
<name><surname>Suriyarachchi</surname><given-names>G.D.</given-names></name>
<name><surname>Paul</surname><given-names>S.S.</given-names></name>
<name><surname>Song</surname><given-names>J.</given-names></name>
<name><surname>Canning</surname><given-names>C.G.</given-names></name>
</person-group><article-title>Exercise and motor training in people with Parkinson&#x02019;s disease: A systematic review of participant characteristics, intervention delivery, retention rates, adherence, and adverse events in clinical trials</article-title><source>Park. Dis.</source><year>2012</year><volume>2012</volume><fpage>854328</fpage><pub-id pub-id-type="doi">10.1155/2012/854328</pub-id></element-citation></ref><ref id="B5-sensors-24-08188"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Perez-Lloret</surname><given-names>S.</given-names></name>
<name><surname>Rey</surname><given-names>M.V.</given-names></name>
<name><surname>Fabre</surname><given-names>N.</given-names></name>
<name><surname>Ory</surname><given-names>F.</given-names></name>
<name><surname>Spampinato</surname><given-names>U.</given-names></name>
<name><surname>Montastruc</surname><given-names>J.L.</given-names></name>
<name><surname>Rascol</surname><given-names>O.</given-names></name>
</person-group><article-title>Do Parkinson&#x02019;s disease patients disclose their adverse events spontaneously?</article-title><source>Eur. J. Clin. Pharmacol.</source><year>2012</year><volume>68</volume><fpage>857</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.1007/s00228-011-1198-x</pub-id><pub-id pub-id-type="pmid">22205275</pub-id>
</element-citation></ref><ref id="B6-sensors-24-08188"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cani&#x000e7;a</surname><given-names>V.</given-names></name>
<name><surname>Bou&#x000e7;a-Machado</surname><given-names>R.</given-names></name>
<name><surname>Rosa</surname><given-names>M.M.</given-names></name>
<name><surname>Ferreira</surname><given-names>J.J.</given-names></name>
<name><surname>Group</surname><given-names>C.N.S.P.S.</given-names></name>
</person-group><article-title>Adverse Events of Physiotherapy Interventions in Parkinsonian Patients</article-title><source>Mov. Disord. Clin. Pract.</source><year>2022</year><volume>9</volume><fpage>744</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.1002/mdc3.13466</pub-id><pub-id pub-id-type="pmid">35937480</pub-id>
</element-citation></ref><ref id="B7-sensors-24-08188"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mirelman</surname><given-names>A.</given-names></name>
<name><surname>Rochester</surname><given-names>L.</given-names></name>
<name><surname>Maidan</surname><given-names>I.</given-names></name>
<name><surname>Del Din</surname><given-names>S.</given-names></name>
<name><surname>Alcock</surname><given-names>L.</given-names></name>
<name><surname>Nieuwhof</surname><given-names>F.</given-names></name>
<name><surname>Rikkert</surname><given-names>M.O.</given-names></name>
<name><surname>Bloem</surname><given-names>B.R.</given-names></name>
<name><surname>Pelosin</surname><given-names>E.</given-names></name>
<name><surname>Avanzino</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Addition of a non-immersive virtual reality component to treadmill training to reduce fall risk in older adults (V-TIME): A randomised controlled trial</article-title><source>Lancet</source><year>2016</year><volume>388</volume><fpage>1170</fpage><lpage>1182</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)31325-3</pub-id><pub-id pub-id-type="pmid">27524393</pub-id>
</element-citation></ref><ref id="B8-sensors-24-08188"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>van der Kolk</surname><given-names>N.M.</given-names></name>
<name><surname>de Vries</surname><given-names>N.M.</given-names></name>
<name><surname>Kessels</surname><given-names>R.P.C.</given-names></name>
<name><surname>Joosten</surname><given-names>H.</given-names></name>
<name><surname>Zwinderman</surname><given-names>A.H.</given-names></name>
<name><surname>Post</surname><given-names>B.</given-names></name>
<name><surname>Bloem</surname><given-names>B.R.</given-names></name>
</person-group><article-title>Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson&#x02019;s disease: A double-blind, randomised controlled trial</article-title><source>Lancet Neurol.</source><year>2019</year><volume>18</volume><fpage>998</fpage><lpage>1008</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(19)30285-6</pub-id><pub-id pub-id-type="pmid">31521532</pub-id>
</element-citation></ref><ref id="B9-sensors-24-08188"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maggio</surname><given-names>M.G.</given-names></name>
<name><surname>De Cola</surname><given-names>M.C.</given-names></name>
<name><surname>Latella</surname><given-names>D.</given-names></name>
<name><surname>Maresca</surname><given-names>G.</given-names></name>
<name><surname>Finocchiaro</surname><given-names>C.</given-names></name>
<name><surname>La Rosa</surname><given-names>G.</given-names></name>
<name><surname>Cimino</surname><given-names>V.</given-names></name>
<name><surname>Sorbera</surname><given-names>C.</given-names></name>
<name><surname>Bramanti</surname><given-names>P.</given-names></name>
<name><surname>De Luca</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>What About the Role of Virtual Reality in Parkinson Disease&#x02019;s Cognitive Rehabilitation? Preliminary Findings From a Randomized Clinical Trial</article-title><source>J. Geriatr. Psychiatry Neurol.</source><year>2018</year><volume>31</volume><fpage>312</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1177/0891988718807973</pub-id><pub-id pub-id-type="pmid">30360679</pub-id>
</element-citation></ref><ref id="B10-sensors-24-08188"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Santos</surname><given-names>P.</given-names></name>
<name><surname>Machado</surname><given-names>T.</given-names></name>
<name><surname>Santos</surname><given-names>L.</given-names></name>
<name><surname>Ribeiro</surname><given-names>N.</given-names></name>
<name><surname>Melo</surname><given-names>A.</given-names></name>
</person-group><article-title>Efficacy of the Nintendo Wii combination with Conventional Exercises in the rehabilitation of individuals with Parkinson&#x02019;s disease: A randomized clinical trial</article-title><source>NeuroRehabilitation</source><year>2019</year><volume>45</volume><fpage>255</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.3233/NRE-192771</pub-id><pub-id pub-id-type="pmid">31498138</pub-id>
</element-citation></ref><ref id="B11-sensors-24-08188"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dockx</surname><given-names>K.</given-names></name>
<name><surname>Bekkers</surname><given-names>E.M.</given-names></name>
<name><surname>Van den Bergh</surname><given-names>V.</given-names></name>
<name><surname>Ginis</surname><given-names>P.</given-names></name>
<name><surname>Rochester</surname><given-names>L.</given-names></name>
<name><surname>Hausdorff</surname><given-names>J.M.</given-names></name>
<name><surname>Mirelman</surname><given-names>A.</given-names></name>
<name><surname>Nieuwboer</surname><given-names>A.</given-names></name>
</person-group><article-title>Virtual reality for rehabilitation in Parkinson&#x02019;s disease</article-title><source>Cochrane Database Syst. Rev.</source><year>2016</year><volume>12</volume><fpage>CD010760</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD010760.pub2</pub-id><pub-id pub-id-type="pmid">28000926</pub-id>
</element-citation></ref><ref id="B12-sensors-24-08188"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>J.</given-names></name>
<name><surname>Wu</surname><given-names>J.</given-names></name>
<name><surname>Lu</surname><given-names>J.</given-names></name>
<name><surname>Wei</surname><given-names>X.</given-names></name>
<name><surname>Zheng</surname><given-names>K.</given-names></name>
<name><surname>Liu</surname><given-names>B.</given-names></name>
<name><surname>Xiao</surname><given-names>W.</given-names></name>
<name><surname>Shi</surname><given-names>Q.</given-names></name>
<name><surname>Xiong</surname><given-names>L.</given-names></name>
<name><surname>Ren</surname><given-names>Z.</given-names></name>
</person-group><article-title>Efficacy of virtual reality training on motor performance, activity of daily living, and quality of life in patients with Parkinson&#x02019;s disease: An umbrella review comprising meta-analyses of randomized controlled trials</article-title><source>J. Neuroeng. Rehabil.</source><year>2023</year><volume>20</volume><fpage>133</fpage><pub-id pub-id-type="doi">10.1186/s12984-023-01256-y</pub-id><pub-id pub-id-type="pmid">37777748</pub-id>
</element-citation></ref><ref id="B13-sensors-24-08188"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saredakis</surname><given-names>D.</given-names></name>
<name><surname>Szpak</surname><given-names>A.</given-names></name>
<name><surname>Birckhead</surname><given-names>B.</given-names></name>
<name><surname>Keage</surname><given-names>H.A.D.</given-names></name>
<name><surname>Rizzo</surname><given-names>A.</given-names></name>
<name><surname>Loetscher</surname><given-names>T.</given-names></name>
</person-group><article-title>Factors Associated With Virtual Reality Sickness in Head-Mounted Displays: A Systematic Review and Meta-Analysis</article-title><source>Front. Hum. Neurosci.</source><year>2020</year><volume>14</volume><elocation-id>96</elocation-id><pub-id pub-id-type="doi">10.3389/fnhum.2020.00096</pub-id><pub-id pub-id-type="pmid">32300295</pub-id>
</element-citation></ref><ref id="B14-sensors-24-08188"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rose</surname><given-names>T.</given-names></name>
<name><surname>Nam</surname><given-names>C.S.</given-names></name>
<name><surname>Chen</surname><given-names>K.B.</given-names></name>
</person-group><article-title>Immersion of virtual reality for rehabilitation&#x02014;Review</article-title><source>Appl. Ergon.</source><year>2018</year><volume>69</volume><fpage>153</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/j.apergo.2018.01.009</pub-id><pub-id pub-id-type="pmid">29477323</pub-id>
</element-citation></ref><ref id="B15-sensors-24-08188"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>A.</given-names></name>
<name><surname>Darakjian</surname><given-names>N.</given-names></name>
<name><surname>Finley</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Walking in fully immersive virtual environments: An evaluation of potential adverse effects in older adults and individuals with Parkinson&#x02019;s disease</article-title><source>J. Neuroeng. Rehabil.</source><year>2017</year><volume>14</volume><fpage>16</fpage><pub-id pub-id-type="doi">10.1186/s12984-017-0225-2</pub-id><pub-id pub-id-type="pmid">28222783</pub-id>
</element-citation></ref><ref id="B16-sensors-24-08188"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brand&#x000ed;n-De la Cruz</surname><given-names>N.</given-names></name>
<name><surname>Secorro</surname><given-names>N.</given-names></name>
<name><surname>Calvo</surname><given-names>S.</given-names></name>
<name><surname>Benyoucef</surname><given-names>Y.</given-names></name>
<name><surname>Herrero</surname><given-names>P.</given-names></name>
<name><surname>Bellosta-L&#x000f3;pez</surname><given-names>P.</given-names></name>
</person-group><article-title>Immersive virtual reality and antigravity treadmill training for gait rehabilitation in Parkinson&#x02019;s disease: A pilot and feasibility study</article-title><source>Rev. Neurol.</source><year>2020</year><volume>71</volume><fpage>447</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.33588/rn.7112.2020352</pub-id><pub-id pub-id-type="pmid">33319347</pub-id>
</element-citation></ref><ref id="B17-sensors-24-08188"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bouca-Machado</surname><given-names>R.</given-names></name>
<name><surname>Duarte</surname><given-names>G.S.</given-names></name>
<name><surname>Patriarca</surname><given-names>M.</given-names></name>
<name><surname>Castro Caldas</surname><given-names>A.</given-names></name>
<name><surname>Alarcao</surname><given-names>J.</given-names></name>
<name><surname>Fernandes</surname><given-names>R.M.</given-names></name>
<name><surname>Mestre</surname><given-names>T.A.</given-names></name>
<name><surname>Matias</surname><given-names>R.</given-names></name>
<name><surname>Ferreira</surname><given-names>J.J.</given-names></name>
</person-group><article-title>Measurement Instruments to Assess Functional Mobility in Parkinson&#x02019;s Disease: A Systematic Review</article-title><source>Mov. Disord. Clin. Pract.</source><year>2020</year><volume>7</volume><fpage>129</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1002/mdc3.12874</pub-id><pub-id pub-id-type="pmid">32071930</pub-id>
</element-citation></ref><ref id="B18-sensors-24-08188"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bloem</surname><given-names>B.R.</given-names></name>
<name><surname>Marinus</surname><given-names>J.</given-names></name>
<name><surname>Almeida</surname><given-names>Q.</given-names></name>
<name><surname>Dibble</surname><given-names>L.</given-names></name>
<name><surname>Nieuwboer</surname><given-names>A.</given-names></name>
<name><surname>Post</surname><given-names>B.</given-names></name>
<name><surname>Ruzicka</surname><given-names>E.</given-names></name>
<name><surname>Goetz</surname><given-names>C.</given-names></name>
<name><surname>Stebbins</surname><given-names>G.</given-names></name>
<name><surname>Martinez-Martin</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Measurement instruments to assess posture, gait, and balance in Parkinson&#x02019;s disease: Critique and recommendations</article-title><source>Mov. Disord.</source><year>2016</year><volume>31</volume><fpage>1342</fpage><lpage>1355</lpage><pub-id pub-id-type="doi">10.1002/mds.26572</pub-id><pub-id pub-id-type="pmid">26945525</pub-id>
</element-citation></ref><ref id="B19-sensors-24-08188"><label>19.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use</collab>
</person-group><article-title>Clinical Safety Data Management: Definitions and Standards for Expedited Reporting E2A</article-title><comment>Available online: <ext-link xlink:href="https://database.ich.org/sites/default/files/E2A_Guideline.pdf" ext-link-type="uri">https://database.ich.org/sites/default/files/E2A_Guideline.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-11">(accessed on 11 November 2024)</date-in-citation></element-citation></ref><ref id="B20-sensors-24-08188"><label>20.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>U.S. Department of Health and Human Services</collab>
<collab>National Institutes of Health</collab>
<collab>National Cancer Institute</collab>
</person-group><article-title>Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0</article-title><year>2017</year><comment>Available online: <ext-link xlink:href="https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf" ext-link-type="uri">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-11">(accessed on 11 November 2024)</date-in-citation></element-citation></ref><ref id="B21-sensors-24-08188"><label>21.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>FDA</collab>
</person-group><article-title>What Is a Serious Adverse Event?</article-title><comment>Available online: <ext-link xlink:href="https://www.fda.gov/safety/reporting-serious-problems-fda/what-serious-adverse-event" ext-link-type="uri">https://www.fda.gov/safety/reporting-serious-problems-fda/what-serious-adverse-event</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-28">(accessed on 28 October 2024)</date-in-citation></element-citation></ref><ref id="B22-sensors-24-08188"><label>22.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><article-title>The Use of the WHO-UMC System for Standardised Case Causality Assessment</article-title><year>2013</year><comment>Available online: <ext-link xlink:href="https://www.who.int/publications/m/item/WHO-causality-assessment" ext-link-type="uri">https://www.who.int/publications/m/item/WHO-causality-assessment</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-11">(accessed on 11 November 2024)</date-in-citation></element-citation></ref><ref id="B23-sensors-24-08188"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kennedy</surname><given-names>R.S.</given-names></name>
<name><surname>Lane</surname><given-names>N.E.</given-names></name>
<name><surname>Berbaum</surname><given-names>K.S.</given-names></name>
<name><surname>Lilienthal</surname><given-names>M.G.</given-names></name>
</person-group><article-title>Simulator Sickness Questionnaire: An Enhanced Method for Quantifying Simulator Sickness</article-title><source>Int. J. Aviat. Psychol.</source><year>1993</year><volume>3</volume><fpage>203</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1207/s15327108ijap0303_3</pub-id></element-citation></ref><ref id="B24-sensors-24-08188"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carvalho</surname><given-names>M.</given-names></name>
<name><surname>Costa</surname><given-names>R.</given-names></name>
<name><surname>Nardi</surname><given-names>A.</given-names></name>
</person-group><article-title>Simulator Sickness Questionnaire: Translation and cross-cultural adaptation</article-title><source>J. Bras. Psiquiatr.</source><year>2010</year><volume>60</volume><fpage>247</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1590/S0047-20852011000400003</pub-id></element-citation></ref><ref id="B25-sensors-24-08188"><label>25.</label><element-citation publication-type="confproc"><person-group person-group-type="author">
<name><surname>Bimberg</surname><given-names>P.</given-names></name>
<name><surname>Weissker</surname><given-names>T.</given-names></name>
<name><surname>Kulik</surname><given-names>A.</given-names></name>
</person-group><article-title>On the Usage of the Simulator Sickness Questionnaire for Virtual Reality Research</article-title><source>Proceedings of the 2020 IEEE Conference on Virtual Reality and 3D User Interfaces Abstracts and Workshops (VRW)</source><conf-loc>Atlanta, GA, USA</conf-loc><conf-date>22&#x02013;26 March 2020</conf-date><fpage>464</fpage><lpage>467</lpage></element-citation></ref><ref id="B26-sensors-24-08188"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cikajlo</surname><given-names>I.</given-names></name>
<name><surname>Peterlin Potisk</surname><given-names>K.</given-names></name>
</person-group><article-title>Advantages of using 3D virtual reality based training in persons with Parkinson&#x02019;s disease: A parallel study</article-title><source>J. Neuroeng. Rehabil.</source><year>2019</year><volume>16</volume><fpage>119</fpage><pub-id pub-id-type="doi">10.1186/s12984-019-0601-1</pub-id><pub-id pub-id-type="pmid">31623622</pub-id>
</element-citation></ref><ref id="B27-sensors-24-08188"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Melo</surname><given-names>G.E.L.</given-names></name>
<name><surname>Kleiner</surname><given-names>A.F.R.</given-names></name>
<name><surname>Lopes</surname><given-names>J.B.P.</given-names></name>
<name><surname>Dumont</surname><given-names>A.J.L.</given-names></name>
<name><surname>Lazzari</surname><given-names>R.D.</given-names></name>
<name><surname>Galli</surname><given-names>M.</given-names></name>
<name><surname>Oliveira</surname><given-names>C.S.</given-names></name>
</person-group><article-title>Effect of virtual reality training on walking distance and physical fitness in individuals with Parkinson&#x02019;s disease</article-title><source>NeuroRehabilitation</source><year>2018</year><volume>42</volume><fpage>473</fpage><lpage>480</lpage><pub-id pub-id-type="doi">10.3233/NRE-172355</pub-id><pub-id pub-id-type="pmid">29660956</pub-id>
</element-citation></ref><ref id="B28-sensors-24-08188"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hajebrahimi</surname><given-names>F.</given-names></name>
<name><surname>Velioglu</surname><given-names>H.A.</given-names></name>
<name><surname>Bayraktaroglu</surname><given-names>Z.</given-names></name>
<name><surname>Helvaci Yilmaz</surname><given-names>N.</given-names></name>
<name><surname>Hanoglu</surname><given-names>L.</given-names></name>
</person-group><article-title>Clinical evaluation and resting state fMRI analysis of virtual reality based training in Parkinson&#x02019;s disease through a randomized controlled trial</article-title><source>Sci. Rep.</source><year>2022</year><volume>12</volume><elocation-id>8024</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-022-12061-3</pub-id><pub-id pub-id-type="pmid">35577874</pub-id>
</element-citation></ref><ref id="B29-sensors-24-08188"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kashif</surname><given-names>M.</given-names></name>
<name><surname>Ahmad</surname><given-names>A.</given-names></name>
<name><surname>Bandpei</surname><given-names>M.A.M.</given-names></name>
<name><surname>Gilani</surname><given-names>S.A.</given-names></name>
<name><surname>Hanif</surname><given-names>A.</given-names></name>
<name><surname>Iram</surname><given-names>H.</given-names></name>
</person-group><article-title>Combined effects of virtual reality techniques and motor imagery on balance, motor function and activities of daily living in patients with Parkinson&#x02019;s disease: A randomized controlled trial</article-title><source>BMC Geriatr.</source><year>2022</year><volume>22</volume><elocation-id>381</elocation-id><pub-id pub-id-type="doi">10.1186/s12877-022-03035-1</pub-id><pub-id pub-id-type="pmid">35488213</pub-id>
</element-citation></ref><ref id="B30-sensors-24-08188"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maranesi</surname><given-names>E.</given-names></name>
<name><surname>Casoni</surname><given-names>E.</given-names></name>
<name><surname>Baldoni</surname><given-names>R.</given-names></name>
<name><surname>Barboni</surname><given-names>I.</given-names></name>
<name><surname>Rinaldi</surname><given-names>N.</given-names></name>
<name><surname>Tramontana</surname><given-names>B.</given-names></name>
<name><surname>Amabili</surname><given-names>G.</given-names></name>
<name><surname>Benadduci</surname><given-names>M.</given-names></name>
<name><surname>Barbarossa</surname><given-names>F.</given-names></name>
<name><surname>Luzi</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>The Effect of Non-Immersive Virtual Reality Exergames versus Traditional Physiotherapy in Parkinson&#x02019;s Disease Older Patients: Preliminary Results from a Randomized-Controlled Trial</article-title><source>Int. J. Environ. Res. Public Health</source><year>2022</year><volume>19</volume><elocation-id>14818</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph192214818</pub-id><pub-id pub-id-type="pmid">36429537</pub-id>
</element-citation></ref><ref id="B31-sensors-24-08188"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kwon</surname><given-names>S.H.</given-names></name>
<name><surname>Park</surname><given-names>J.K.</given-names></name>
<name><surname>Koh</surname><given-names>Y.H.</given-names></name>
</person-group><article-title>A systematic review and meta-analysis on the effect of virtual reality-based rehabilitation for people with Parkinson&#x02019;s disease</article-title><source>J. Neuroeng. Rehabil.</source><year>2023</year><volume>20</volume><fpage>94</fpage><pub-id pub-id-type="doi">10.1186/s12984-023-01219-3</pub-id><pub-id pub-id-type="pmid">37475014</pub-id>
</element-citation></ref><ref id="B32-sensors-24-08188"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rodr&#x000ed;guez-Mansilla</surname><given-names>J.</given-names></name>
<name><surname>Bedmar-Vargas</surname><given-names>C.</given-names></name>
<name><surname>Garrido-Ardila</surname><given-names>E.M.</given-names></name>
<name><surname>Torres-Piles</surname><given-names>S.T.</given-names></name>
<name><surname>Gonz&#x000e1;lez-S&#x000e1;nchez</surname><given-names>B.</given-names></name>
<name><surname>Rodr&#x000ed;guez-Dom&#x000ed;nguez</surname><given-names>M.T.</given-names></name>
<name><surname>Ram&#x000ed;rez-Dur&#x000e1;n</surname><given-names>M.V.</given-names></name>
<name><surname>Jim&#x000e9;nez-Palomares</surname><given-names>M.</given-names></name>
</person-group><article-title>Effects of Virtual Reality in the Rehabilitation of Parkinson&#x02019;s Disease: A Systematic Review</article-title><source>J. Clin. Med.</source><year>2023</year><volume>12</volume><elocation-id>4896</elocation-id><pub-id pub-id-type="doi">10.3390/jcm12154896</pub-id><pub-id pub-id-type="pmid">37568298</pub-id>
</element-citation></ref><ref id="B33-sensors-24-08188"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ma</surname><given-names>H.I.</given-names></name>
<name><surname>Hwang</surname><given-names>W.J.</given-names></name>
<name><surname>Fang</surname><given-names>J.J.</given-names></name>
<name><surname>Kuo</surname><given-names>J.K.</given-names></name>
<name><surname>Wang</surname><given-names>C.Y.</given-names></name>
<name><surname>Leong</surname><given-names>I.F.</given-names></name>
<name><surname>Wang</surname><given-names>T.Y.</given-names></name>
</person-group><article-title>Effects of virtual reality training on functional reaching movements in people with Parkinson&#x02019;s disease: A randomized controlled pilot trial</article-title><source>Clin. Rehabil.</source><year>2011</year><volume>25</volume><fpage>892</fpage><lpage>902</lpage><pub-id pub-id-type="doi">10.1177/0269215511406757</pub-id><pub-id pub-id-type="pmid">21632652</pub-id>
</element-citation></ref><ref id="B34-sensors-24-08188"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Robles-Garc&#x000ed;a</surname><given-names>V.</given-names></name>
<name><surname>Corral-Berganti&#x000f1;os</surname><given-names>Y.</given-names></name>
<name><surname>Espinosa</surname><given-names>N.</given-names></name>
<name><surname>Garc&#x000ed;a-Sancho</surname><given-names>C.</given-names></name>
<name><surname>Sanmart&#x000ed;n</surname><given-names>G.</given-names></name>
<name><surname>Flores</surname><given-names>J.</given-names></name>
<name><surname>Cudeiro</surname><given-names>J.</given-names></name>
<name><surname>Arias</surname><given-names>P.</given-names></name>
</person-group><article-title>Effects of movement imitation training in Parkinson&#x02019;s disease: A virtual reality pilot study</article-title><source>Park. Relat. Disord.</source><year>2016</year><volume>26</volume><fpage>17</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2016.02.022</pub-id></element-citation></ref><ref id="B35-sensors-24-08188"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Allen</surname><given-names>N.E.</given-names></name>
<name><surname>Song</surname><given-names>J.</given-names></name>
<name><surname>Paul</surname><given-names>S.S.</given-names></name>
<name><surname>Smith</surname><given-names>S.</given-names></name>
<name><surname>O&#x02019;Duffy</surname><given-names>J.</given-names></name>
<name><surname>Schmidt</surname><given-names>M.</given-names></name>
<name><surname>Love</surname><given-names>R.</given-names></name>
<name><surname>Sherrington</surname><given-names>C.</given-names></name>
<name><surname>Canning</surname><given-names>C.G.</given-names></name>
</person-group><article-title>An interactive videogame for arm and hand exercise in people with Parkinson&#x02019;s disease: A randomized controlled trial</article-title><source>Park. Relat. Disord.</source><year>2017</year><volume>41</volume><fpage>66</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2017.05.011</pub-id></element-citation></ref><ref id="B36-sensors-24-08188"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gandolfi</surname><given-names>M.</given-names></name>
<name><surname>Geroin</surname><given-names>C.</given-names></name>
<name><surname>Dimitrova</surname><given-names>E.</given-names></name>
<name><surname>Boldrini</surname><given-names>P.</given-names></name>
<name><surname>Waldner</surname><given-names>A.</given-names></name>
<name><surname>Bonadiman</surname><given-names>S.</given-names></name>
<name><surname>Picelli</surname><given-names>A.</given-names></name>
<name><surname>Regazzo</surname><given-names>S.</given-names></name>
<name><surname>Stirbu</surname><given-names>E.</given-names></name>
<name><surname>Primon</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Virtual Reality Telerehabilitation for Postural Instability in Parkinson&#x02019;s Disease: A Multicenter, Single-Blind, Randomized, Controlled Trial</article-title><source>BioMed Res. Int.</source><year>2017</year><volume>2017</volume><elocation-id>7962826</elocation-id><pub-id pub-id-type="doi">10.1155/2017/7962826</pub-id><pub-id pub-id-type="pmid">29333454</pub-id>
</element-citation></ref><ref id="B37-sensors-24-08188"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pompeu</surname><given-names>J.E.</given-names></name>
<name><surname>Mendes</surname><given-names>F.A.</given-names></name>
<name><surname>Silva</surname><given-names>K.G.</given-names></name>
<name><surname>Lobo</surname><given-names>A.M.</given-names></name>
<name><surname>Oliveira Tde</surname><given-names>P.</given-names></name>
<name><surname>Zomignani</surname><given-names>A.P.</given-names></name>
<name><surname>Piemonte</surname><given-names>M.E.</given-names></name>
</person-group><article-title>Effect of Nintendo Wii&#x02122;-based motor and cognitive training on activities of daily living in patients with Parkinson&#x02019;s disease: A randomised clinical trial</article-title><source>Physiotherapy</source><year>2012</year><volume>98</volume><fpage>196</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/j.physio.2012.06.004</pub-id><pub-id pub-id-type="pmid">22898575</pub-id>
</element-citation></ref><ref id="B38-sensors-24-08188"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>van den Heuvel</surname><given-names>M.R.</given-names></name>
<name><surname>Kwakkel</surname><given-names>G.</given-names></name>
<name><surname>Beek</surname><given-names>P.J.</given-names></name>
<name><surname>Berendse</surname><given-names>H.W.</given-names></name>
<name><surname>Daffertshofer</surname><given-names>A.</given-names></name>
<name><surname>van Wegen</surname><given-names>E.E.</given-names></name>
</person-group><article-title>Effects of augmented visual feedback during balance training in Parkinson&#x02019;s disease: A pilot randomized clinical trial</article-title><source>Park. Relat. Disord.</source><year>2014</year><volume>20</volume><fpage>1352</fpage><lpage>1358</lpage><pub-id pub-id-type="doi">10.1016/j.parkreldis.2014.09.022</pub-id></element-citation></ref><ref id="B39-sensors-24-08188"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cancela-Carral</surname><given-names>J.M.</given-names></name>
<name><surname>Campo-Prieto</surname><given-names>P.</given-names></name>
<name><surname>Rodriguez-Fuentes</surname><given-names>G.</given-names></name>
</person-group><article-title>The IntegraPark Study: An Opportunity to Facilitate High-Intensity Exercise with Immersive Virtual Reality in Parkinson&#x02019;s Disease Patients</article-title><source>J. Funct. Morphol. Kinesiol.</source><year>2024</year><volume>9</volume><elocation-id>156</elocation-id><pub-id pub-id-type="doi">10.3390/jfmk9030156</pub-id><pub-id pub-id-type="pmid">39311264</pub-id>
</element-citation></ref><ref id="B40-sensors-24-08188"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Campo-Prieto</surname><given-names>P.</given-names></name>
<name><surname>Cancela-Carral</surname><given-names>J.M.</given-names></name>
<name><surname>Rodriguez-Fuentes</surname><given-names>G.</given-names></name>
</person-group><article-title>Wearable Immersive Virtual Reality Device for Promoting Physical Activity in Parkinson&#x02019;s Disease Patients</article-title><source>Sensors</source><year>2022</year><volume>22</volume><elocation-id>3302</elocation-id><pub-id pub-id-type="doi">10.3390/s22093302</pub-id><pub-id pub-id-type="pmid">35590992</pub-id>
</element-citation></ref><ref id="B41-sensors-24-08188"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schenkman</surname><given-names>M.</given-names></name>
<name><surname>Moore</surname><given-names>C.G.</given-names></name>
<name><surname>Kohrt</surname><given-names>W.M.</given-names></name>
<name><surname>Hall</surname><given-names>D.A.</given-names></name>
<name><surname>Delitto</surname><given-names>A.</given-names></name>
<name><surname>Comella</surname><given-names>C.L.</given-names></name>
<name><surname>Josbeno</surname><given-names>D.A.</given-names></name>
<name><surname>Christiansen</surname><given-names>C.L.</given-names></name>
<name><surname>Berman</surname><given-names>B.D.</given-names></name>
<name><surname>Kluger</surname><given-names>B.M.</given-names></name>
<etal/>
</person-group><article-title>Effect of High-Intensity Treadmill Exercise on Motor Symptoms in Patients With De Novo Parkinson Disease: A Phase 2 Randomized Clinical Trial</article-title><source>JAMA Neurol.</source><year>2018</year><volume>75</volume><fpage>219</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2017.3517</pub-id><pub-id pub-id-type="pmid">29228079</pub-id>
</element-citation></ref><ref id="B42-sensors-24-08188"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Uc</surname><given-names>E.Y.</given-names></name>
<name><surname>Doerschug</surname><given-names>K.C.</given-names></name>
<name><surname>Magnotta</surname><given-names>V.</given-names></name>
<name><surname>Dawson</surname><given-names>J.D.</given-names></name>
<name><surname>Thomsen</surname><given-names>T.R.</given-names></name>
<name><surname>Kline</surname><given-names>J.N.</given-names></name>
<name><surname>Rizzo</surname><given-names>M.</given-names></name>
<name><surname>Newman</surname><given-names>S.R.</given-names></name>
<name><surname>Mehta</surname><given-names>S.</given-names></name>
<name><surname>Grabowski</surname><given-names>T.J.</given-names></name>
<etal/>
</person-group><article-title>Phase I/II randomized trial of aerobic exercise in Parkinson disease in a community setting</article-title><source>Neurology</source><year>2014</year><volume>83</volume><fpage>413</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000000644</pub-id><pub-id pub-id-type="pmid">24991037</pub-id>
</element-citation></ref><ref id="B43-sensors-24-08188"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schenkman</surname><given-names>M.</given-names></name>
<name><surname>Hall</surname><given-names>D.A.</given-names></name>
<name><surname>Baron</surname><given-names>A.E.</given-names></name>
<name><surname>Schwartz</surname><given-names>R.S.</given-names></name>
<name><surname>Mettler</surname><given-names>P.</given-names></name>
<name><surname>Kohrt</surname><given-names>W.M.</given-names></name>
</person-group><article-title>Exercise for people in early- or mid-stage Parkinson disease: A 16-month randomized controlled trial</article-title><source>Phys. Ther.</source><year>2012</year><volume>92</volume><fpage>1395</fpage><lpage>1410</lpage><pub-id pub-id-type="doi">10.2522/ptj.20110472</pub-id><pub-id pub-id-type="pmid">22822237</pub-id>
</element-citation></ref><ref id="B44-sensors-24-08188"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Perez-Marcos</surname><given-names>D.</given-names></name>
</person-group><article-title>Virtual reality experiences, embodiment, videogames and their dimensions in neurorehabilitation</article-title><source>J. Neuroeng. Rehabil.</source><year>2018</year><volume>15</volume><fpage>113</fpage><pub-id pub-id-type="doi">10.1186/s12984-018-0461-0</pub-id><pub-id pub-id-type="pmid">30477527</pub-id>
</element-citation></ref><ref id="B45-sensors-24-08188"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mantri</surname><given-names>S.</given-names></name>
<name><surname>Lepore</surname><given-names>M.</given-names></name>
<name><surname>Edison</surname><given-names>B.</given-names></name>
<name><surname>Daeschler</surname><given-names>M.</given-names></name>
<name><surname>Kopil</surname><given-names>C.M.</given-names></name>
<name><surname>Marras</surname><given-names>C.</given-names></name>
<name><surname>Chahine</surname><given-names>L.M.</given-names></name>
</person-group><article-title>The Experience of OFF Periods in Parkinson&#x02019;s Disease: Descriptions, Triggers, and Alleviating Factors</article-title><source>J. Patient Cent. Res. Rev.</source><year>2021</year><volume>8</volume><fpage>232</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.17294/2330-0698.1836</pub-id><pub-id pub-id-type="pmid">34322575</pub-id>
</element-citation></ref><ref id="B46-sensors-24-08188"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Figura</surname><given-names>M.</given-names></name>
<name><surname>Mrozowicz</surname><given-names>A.</given-names></name>
<name><surname>Milanowski</surname><given-names>&#x00141;.</given-names></name>
<name><surname>Szlufik</surname><given-names>S.</given-names></name>
<name><surname>Ra&#x00107;kowska</surname><given-names>E.</given-names></name>
<name><surname>Lypkan</surname><given-names>H.</given-names></name>
<name><surname>Friedman</surname><given-names>A.</given-names></name>
<name><surname>Koziorowski</surname><given-names>D.</given-names></name>
<name><surname>Giebu&#x00142;towicz</surname><given-names>J.</given-names></name>
</person-group><article-title>Impact of Physical Exercise on Levodopa Therapy Across Parkinson&#x02019;s Disease Stages</article-title><source>J. Parkinsons Dis.</source><year>2024</year><volume>14</volume><fpage>1039</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.3233/JPD-230384</pub-id><pub-id pub-id-type="pmid">38905055</pub-id>
</element-citation></ref><ref id="B47-sensors-24-08188"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>I.</given-names></name>
<name><surname>Edison</surname><given-names>B.</given-names></name>
<name><surname>Mantri</surname><given-names>S.</given-names></name>
<name><surname>Albert</surname><given-names>S.</given-names></name>
<name><surname>Daeschler</surname><given-names>M.</given-names></name>
<name><surname>Kopil</surname><given-names>C.</given-names></name>
<name><surname>Marras</surname><given-names>C.</given-names></name>
<name><surname>Chahine</surname><given-names>L.M.</given-names></name>
</person-group><article-title>Triggers and alleviating factors for fatigue in Parkinson&#x02019;s disease</article-title><source>PLoS ONE</source><year>2021</year><volume>16</volume><elocation-id>e0245285</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0245285</pub-id><pub-id pub-id-type="pmid">33540422</pub-id>
</element-citation></ref><ref id="B48-sensors-24-08188"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rodr&#x000ed;guez-Fuentes</surname><given-names>G.</given-names></name>
<name><surname>Campo-Prieto</surname><given-names>P.</given-names></name>
<name><surname>Cancela-Carral</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Immersive Virtual Reality High-Intensity Aerobic Training to Slow Parkinson&#x02019;s Disease: The ReViPark Program</article-title><source>Appl. Sci.</source><year>2024</year><volume>14</volume><elocation-id>4708</elocation-id><pub-id pub-id-type="doi">10.3390/app14114708</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="sensors-24-08188-f001"><label>Figure 1</label><caption><p>Warm-up funfair scenario. Available at the Steam VR platform.</p></caption><graphic xlink:href="sensors-24-08188-g001" position="float"/></fig><fig position="float" id="sensors-24-08188-f002"><label>Figure 2</label><caption><p>Evolution of the Simulator Sickness Questionnaire (SSQ) scores over time by study group. VRG&#x02014;virtual reality group; SG&#x02014;sequential group.</p></caption><graphic xlink:href="sensors-24-08188-g002" position="float"/></fig><table-wrap position="float" id="sensors-24-08188-t001"><object-id pub-id-type="pii">sensors-24-08188-t001_Table 1</object-id><label>Table 1</label><caption><p>Baseline participants&#x02019; characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">VR Group (<italic toggle="yes">n</italic> = 15)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sequential Group (<italic toggle="yes">n</italic> = 15)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age (years), median [IQR]</td><td align="center" valign="middle" rowspan="1" colspan="1">61 [58, 66]</td><td align="center" valign="middle" rowspan="1" colspan="1">68 [62, 72.5]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Gender (men), n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (60)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (53.3)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Education, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Low</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (33.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (46.7)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Medium</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (26.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.07)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;High</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (40)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (46.7)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Disease duration (years), median [IQR]</td><td align="center" valign="middle" rowspan="1" colspan="1">7 [6, 10]</td><td align="center" valign="middle" rowspan="1" colspan="1">9 [5, 11.5]</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">First symptom, n (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Tremor</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (46.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (46.7)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Bradykinesia-rigidity</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (46.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (46.7)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Other</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.07)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.07)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MDS-UPDRS part 3, median [IQR]</td><td align="center" valign="middle" rowspan="1" colspan="1">31 [23, 35.5]</td><td align="center" valign="middle" rowspan="1" colspan="1">23 [13, 24.5]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HY, median [IQR]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 [2, 2]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 [2, 2]</td></tr></tbody></table><table-wrap-foot><fn><p>IQR&#x02014;interquartile range (25th percentile; 75th percentile); MDS-UPDRS&#x02014;Movement Disorder Society Unified Parkinson&#x02019;s Disease Rating Scale; HY&#x02014;Hoehn and Yahr.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="sensors-24-08188-t002"><object-id pub-id-type="pii">sensors-24-08188-t002_Table 2</object-id><label>Table 2</label><caption><p>Reported adverse events.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Adverse Event (AE)</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">N (%)</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">VR Group</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Sequential Group</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#x02013;6 Week</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6&#x02013;12 Week</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#x02013;6 Week</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6&#x02013;12 Week</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Discomfort/pain</td><td align="center" valign="middle" rowspan="1" colspan="1">46 (2.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">15 (2.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (1.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (2.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">20 (4.3)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Motor fluctuations</td><td align="center" valign="middle" rowspan="1" colspan="1">34 (2.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">16 (3.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (2.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (0.7)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Falls</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (0.6) </td><td align="center" valign="middle" rowspan="1" colspan="1">3 (0.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (1.3)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Fatigue</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (0.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (0.7)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Near falls</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (0.5) </td><td align="center" valign="middle" rowspan="1" colspan="1">4 (0.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0.4)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hypotension</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (0.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (1.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Dizziness</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (0.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0.4)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hyperhidrosis</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (0.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (0.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Dyskinesias</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (0.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (0.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Irritability/frustration</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gut disturbance</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Headache</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Impulse control disorder</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Muscle soreness</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hypertension</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.06)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Numbness/tingling</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.06)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Syncope</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.06)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sleep disturbance</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.06)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Dry mouth</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.06)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Hematuria</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.06)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cramps</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.06)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gout</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.06)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Chin rash</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.06)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Complicated hernia</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.06)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Flu-like symptoms</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.06)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Total</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">144 (8.4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">57 (11.2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29 (5.8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15 (6.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">43 (9.3)</td></tr></tbody></table><table-wrap-foot><fn><p>Values are presented as the total count of occurrences throughout this study and as the percentage relative to the total number of attended sessions, per group. Attendance was as follows: total attended sessions = 1717; sessions attended by the VR group = 1012 (0&#x02013;6 week = 510 sessions, 6&#x02013;12 week = 502 sessions); and by the sequential group = 705 (0&#x02013;6 week = 245 sessions, 6&#x02013;12 week = 460 sessions).</p></fn></table-wrap-foot></table-wrap></floats-group></article>